Literature DB >> 17029061

Clinical characteristics of Pneumocystis carinii pneumonia in patients with connective tissue diseases.

Takeo Sato1, Shigeko Inokuma, Reika Maezawa, Hisanori Nakayama, Ken Hamasaki, Yusuke Miwa, Yuko Okazaki, Masahiro Yamashita, Yoshiaki Tanaka, Hajime Kono.   

Abstract

The characteristics of Pneumocystis carinii pneumonia (PCP) in patients with connective tissue diseases (CTDs) were examined retrospectively. Nine patients were enrolled in this study. Their mean age was 57.1 years. All the patients received a high-dose steroid or immunosuppressant. The onset (mean 6.6 days) of fever, cough, breathlessness, and geographical ground-glass opacities revealed by chest computed tomography was acute. The serum beta-D: -glucan level increased with a simultaneous increase in the Krebs von den Lungen (KL)-6 or surfactant protein D level. The serum immunoglobulin G (IgG) and albumin levels and the peripheral blood lymphocyte count at the onset of PCP were low, but only the serum IgG level decreased significantly. The patients were treated with trimethoprim-sulfamethoxazole or pentamidine isetionate. Six patients died eventually: two patients of progressive respiratory failure, two probably due to a recurrence of the PCP, and two with microbial respiratory infections other than PCP. Five of the six patients required mechanical ventilation. Three patients received secondary prophylaxis and survived. In conclusion, the acute onset was characteristic of PCP in patients with CTDs. High-dose steroids, immunosuppressants, and hypogammaglobulinemia are risk factors; and respiratory failure requiring mechanical ventilation, severe secondary infections, and a lack of secondary prophylaxis are poor prognostic factors. Secondary prophylaxis is recommended for all of these patients.

Entities:  

Year:  2005        PMID: 17029061     DOI: 10.1007/s10165-005-0395-9

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  9 in total

1.  Combine use of glucocorticoid with other immunosuppressants is a risk factor for Pneumocystis jirovecii pneumonia in autoimmune inflammatory disease patients: a meta-analysis.

Authors:  Huyu Wang; Lili Shui; Yajuan Chen
Journal:  Clin Rheumatol       Date:  2022-09-23       Impact factor: 3.650

2.  Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases.

Authors:  Yoko Aoki; Masahiro Iwamoto; Yasuyuki Kamata; Takao Nagashima; Taku Yoshio; Hitoaki Okazaki; Seiji Minota
Journal:  Rheumatol Int       Date:  2009-01-14       Impact factor: 2.631

3.  Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases.

Authors:  Yongfeng Zhang; Yi Zheng
Journal:  Rheumatol Int       Date:  2014-06-20       Impact factor: 2.631

4.  Late-onset and atypical presentation of Pneumocystis carinii pneumonia in a renal transplant recipient.

Authors:  Jordan Y Z Li; Tuck Y Yong; David I Grove; P Toby H Coates
Journal:  Clin Exp Nephrol       Date:  2008-08-30       Impact factor: 2.801

Review 5.  Pneumocystis jirovecii Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis Recommendations.

Authors:  Shunsuke Mori; Mineharu Sugimoto
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-09-06

Review 6.  Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis.

Authors:  Shunsuke Mori; Mineharu Sugimoto
Journal:  Rheumatology (Oxford)       Date:  2012-09-22       Impact factor: 7.580

7.  Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease.

Authors:  Miho Kimura; Sumiaki Tanaka; Akira Ishikawa; Hirahito Endo; Shunsei Hirohata; Hirobumi Kondo
Journal:  Rheumatol Int       Date:  2007-12-14       Impact factor: 3.580

8.  Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study.

Authors:  Takayuki Katsuyama; Kazuyoshi Saito; Satoshi Kubo; Masao Nawata; Yoshiya Tanaka
Journal:  Arthritis Res Ther       Date:  2014-02-05       Impact factor: 5.156

Review 9.  A Rare Case of Ulcerative Colitis with Severe Pneumocystis jirovecii Pneumonia and Cytomegalovirus Colitis: A Case Report and Literature Review.

Authors:  Yusuke Watanabe; Kazunao Hayashi; Shuji Terai
Journal:  Intern Med       Date:  2021-08-06       Impact factor: 1.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.